Document Detail

New promising anticancer agents in development: what comes next?
MedLine Citation:
PMID:  8765408     Owner:  NLM     Status:  MEDLINE    
Anticancer drug development has recently shifted in part to development of more innovative anticancer agents. The increasing knowledge of the pathogenetic mechanisms involved in cancer cell growth has enabled the introduction of drug screening that is more mechanism-based. The realization that new targets should be preferentially evaluated as sites for anticancer drug treatment has led to the introduction of drugs such as the taxanes. Following this logic, several new drugs are being developed. Minor groove-binding agents such as carzelesin and oral platins lacking organ toxicity, such as JM216, have recently entered clinical studies. The activity of gemcitabine is a result of its being a cytidine analogue and being competitively incorporated by DNA; the drug has shown interesting activity in non-small-cell lung cancer and, although registration is imminent, issues regarding the optimal dose and administration schedule have yet to be resolved. Tomudex is a thymidylate synthase inhibitor with interesting activity in colorectal cancer. Activity in colorectal cancer is also of interest for irinotecan, the first clinically applied topoisomerase I inhibitor, an enzyme that is another example of a new target for anticancer drugs. Irinotecan has produced consistent response rates of 20-30% in six different studies in colorectal cancer. The other topoisomerase I inhibitor that is in the advanced stage of development is topotecan. This drug has shown activity in second-line chemotherapy for ovarian cancer and small-cell lung cancer. Another interesting feature of topotecan is the availability of an oral formulation with consistent bioavailability. Drugs interfering with cellular signal transduction, such as the protein kinase C inhibitors, are in the development spotlight. Finally, the use of old drugs in new ways, such as immunoconjugates of doxorubicin, holds promise for the near future.
J Verweij
Related Documents :
12889738 - Use of positron emission tomography in anticancer drug development.
18698718 - The degradation pathways in chloride medium of the third generation anticancer drug oxa...
16168568 - Individualized cancer chemotherapy integrating drug sensitivity tests, pathological pro...
10699308 - Noninvasive measurements for studying the tumoral pharmacokinetics of platinum anticanc...
22014248 - The substance abuse counseling workforce: education, preparation, and certification.
24297538 - Computational approaches to drug repurposing and pharmacolog- session introduction.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Cancer chemotherapy and pharmacology     Volume:  38 Suppl     ISSN:  0344-5704     ISO Abbreviation:  Cancer Chemother. Pharmacol.     Publication Date:  1996  
Date Detail:
Created Date:  1996-09-17     Completed Date:  1996-09-17     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  7806519     Medline TA:  Cancer Chemother Pharmacol     Country:  GERMANY    
Other Details:
Languages:  eng     Pagination:  S3-10     Citation Subset:  IM    
Department of Medical Oncology, Rotterdam Cancer Institute (Daniel den Hoed Kliniek), The Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Agents / therapeutic use*
Clinical Trials as Topic
Drugs, Investigational / therapeutic use*
Neoplasms / drug therapy*
Reg. No./Substance:
0/Antineoplastic Agents; 0/Drugs, Investigational

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Severe metabolic alkalosis with a consciousness disorder
Next Document:  Antitumor activity of interleukin 12 in preclinical models.